Merck Analysts Slash Their Forecasts After Q2 Results
Merck Analysts Slash Their Forecasts After Q2 Results
The U.S. pharma giant expects 2024 adjusted EPS of $7.94 to $8.04, compared to prior guidance of $8.53-$8.65 and consensus of $8.16. The outlook includes one-time charges of $0.77 per share For Harpoon and Eyebio acquisitions.Merck & Co Inc (NYSE:MRK) reported better-than-expected second-quarter earnings and sales results on Tuesday.
默沙东公司（NYSE:MRK）于周二发布了超出预期的第二季度收益和销售业绩。
The company posted quarterly sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%. Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15.
该公司发布季度销售额为161亿美元，同比增长7％，超过了158.4亿美元的共识估计。不包括外汇影响，销售额增长了11%。默沙东公司报告调整后的每股收益为2.28美元，转变为每股亏损（2.06）美元，超过了2.15美元的共识。
Merck revised and narrowed its full-year 2024 forecasts. The company expects 2024 sales of $63.4 billion—$64.4 billion, compared to previous guidance of $63.1 billion—$64.3 billion and the consensus of $64.34 billion.
默沙东公司修订并缩小了其2024年全年预测范围。该公司预计2024年销售额为634亿至644亿美元，相比之前的指引631亿至643亿美元和共识643.4亿美元有所增长。
The U.S. pharma giant expects 2024 adjusted EPS of $7.94 to $8.04, compared to prior guidance of $8.53-$8.65 and consensus of $8.16. The outlook includes one-time charges of $0.77 per share For Harpoon and Eyebio acquisitions.
这家美国制药巨头预计2024年调整后的每股收益为7.94至8.04美元，而之前的指引为8.53-8.65美元和8.16美元的共识。展望包括Harpoon和Eyebio收购的一次性费用每股0.77美元。
Merck shares fell 1.6% to trade at $113.37 on Wednesday.
默沙东公司的股价于周三下跌1.6％，报价113.37美元。
These analysts made changes to their price targets on Merck following earnings announcement.
这些分析师在财报公布后对默沙东的价格目标进行了更改。
- UBS analyst Colin Bristow maintained Merck with a Buy and lowered the price target from $148 to $142.
- Wells Fargo analyst Mohit Bansal maintained the stock with an Equal-Weight and cut the price target from $140 to $125.
- B of A Securities analyst Geoff Meacham maintained Merck with a Buy and lowered the price target from $150 to $145.
- 瑞银分析师Colin Bristow对默沙东的买入评级和股价目标从148美元下调至142美元。
- 富国银行分析师Mohit Bansal维持公司的中性评级，将股价目标从140美元下调至125美元。
- BofA证券分析师Geoff Meacham维持默沙东的买入评级，将股价目标从150美元下调至145美元。
- Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: 'I Would Pick Some Up Tomorrow'
- 吉姆·克雷默表示，在联邦基金利率下调周期之前，这家家居改善连锁店是一个买入的选择：“我会在明天买进一些股票。”
